Literature DB >> 12744366

Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible?

Naohiro Tsuyuguchi1, Ichiro Sunada, Yoshiyasu Iwai, Kazuhiro Yamanaka, Kiyoaki Tanaka, Toshihiro Takami, Yumiko Otsuka, Shinichi Sakamoto, Kenji Ohata, Takeo Goto, Mitsuhiro Hara.   

Abstract

OBJECT: In this study the authors examined how to differentiate radiation necrosis from recurrent metastatic brain tumor following stereotactic radiosurgery by using positron emission tomography (PET) with L-[methyl-11C]methionine (MET).
METHODS: In 21 adult patients with suspected recurrent metastatic brain tumor or radiation injury, MET-PET scans were obtained. These patients had previously undergone stereotactic radiosurgery and subsequent contrast-enhanced magnetic resonance (MR) examinations before nuclear medicine imaging. Positron emission tomography images were obtained as a static scan of 10 minutes performed 20 minutes after injection of 370 MBq of MET. On MET-PET scans, the portion of the tumor with the highest accumulation of MET was selected as the region of interest (ROI), and the ratio of tumor tissue to normal tissue (T/N) was defined as the mean counts of radioisotope per pixel in the tumor divided by the mean counts per pixel in normal gray matter. The standardized uptake value (SUV) was calculated using the same ROI in the tumor. The accuracy of the MET-PET scan was evaluated by correlating findings with results of subsequent histological analysis (11 cases) or, in cases in which surgery or biopsy was not performed, with subsequent clinical course and MR imaging findings (10 cases). Histological examinations performed in 11 cases showed viable tumor cells with necrosis in nine and necrosis with no viable tumor cells in two. Another 10 cases were characterized as radiation necrosis because the patients exhibited stable neurological symptoms with no sign of massive enlargement of the lesion on follow-up MR images after 5 months. The mean T/N was 1.15 in the radiation necrosis group (12 cases) and 1.62 in the tumor recurrence group (nine cases). The mean SUV was 1.78 in the necrosis group and 2.5 in the recurrence group. There were statistically significant differences between the recurrence and necrosis groups in T/N and SUV. Furthermore, the borderline T/N value was 1,42 according to a 2 x 2 factorial table (high T/N or low T/N, recurrence or necrosis). From this result, the sensitivity and specificity of MET-PET scanning in detecting tumor recurrence were determined to be 77.8 and 100%, respectively.
CONCLUSIONS: The use of MET-PET scanning is a sensitive and accurate technique for differentiating between metastatic brain tumor recurrence and radiation necrosis following stereotactic radiosurgery. This study reveals important information for creating strategies to treat postradiation reactions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12744366     DOI: 10.3171/jns.2003.98.5.1056

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  65 in total

Review 1.  Applications of positron emission tomography (PET) in neurology.

Authors:  Y F Tai; P Piccini
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

Review 2.  Treatment induced necrosis versus recurrent/progressing brain tumor: going beyond the boundaries of conventional morphologic imaging.

Authors:  Rajan Jain; Jayant Narang; Pia M Sundgren; David Hearshen; Sona Saksena; Jack P Rock; Jorge Gutierrez; Tom Mikkelsen
Journal:  J Neurooncol       Date:  2010-02-24       Impact factor: 4.130

3.  Value of 123I-IMT SPECT for diagnosis of recurrent non-astrocytic intracranial tumours.

Authors:  Michail Plotkin; Holger Amthauer; Julia Eisenacher; Reinhard Wurm; Roger Michel; Peter Wust; Florian Stockhammer; Rainer Röttgen; Matthias Gutberlet; Juri Ruf; Roland Felix
Journal:  Neuroradiology       Date:  2005-01-04       Impact factor: 2.804

Review 4.  Metastatic disease of the brain: parenchyma.

Authors:  Gaida Krumina
Journal:  Eur Radiol       Date:  2005-02-05       Impact factor: 5.315

5.  Spinal intramedullary metastasis of medulloblastoma at initial diagnosis.

Authors:  Tomoo Inoue; Toshihiro Kumabe; Toshiyuki Takahashi; Takeshi Nakajima; Mika Watanabe; Teiji Tominaga
Journal:  Childs Nerv Syst       Date:  2006-10-28       Impact factor: 1.475

Review 6.  Defining the endpoints: how to measure the efficacy of drugs that are active against central nervous system metastases.

Authors:  Alessandra Fabi; Antonello Vidiri
Journal:  Transl Lung Cancer Res       Date:  2016-12

Review 7.  Molecular imaging of brain tumors: a bridge between clinical and molecular medicine?

Authors:  B J Schaller; M Modo; M Buchfelder
Journal:  Mol Imaging Biol       Date:  2007 Mar-Apr       Impact factor: 3.488

8.  Perfusion weighted magnetic resonance imaging to distinguish the recurrence of metastatic brain tumors from radiation necrosis after stereotactic radiosurgery.

Authors:  Koichi Mitsuya; Yoko Nakasu; Satoshi Horiguchi; Hideyuki Harada; Tetsuo Nishimura; Etsuro Bando; Hiroto Okawa; Yoshihiro Furukawa; Tatsuo Hirai; Masahiro Endo
Journal:  J Neurooncol       Date:  2010-01-08       Impact factor: 4.130

9.  Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma.

Authors:  Gabriele Pöpperl; Claudia Götz; Walter Rachinger; Franz-Josef Gildehaus; Jörg-Christian Tonn; Klaus Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-10       Impact factor: 9.236

10.  Salvage stereotactic radiosurgery with adjuvant use of bevacizumab for heavily treated recurrent brain metastases: a preliminary report.

Authors:  Shoji Yomo; Motohiro Hayashi
Journal:  J Neurooncol       Date:  2015-11-30       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.